Mark J. Ratain to Skin Neoplasms
This is a "connection" page, showing publications Mark J. Ratain has written about Skin Neoplasms.
Connection Strength
0.112
-
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
Score: 0.034
-
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
Score: 0.029
-
Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol. 1996 Jan; 132(1):96-8.
Score: 0.024
-
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor. Ann Oncol. 1991 Jul; 2(7):522-3.
Score: 0.018
-
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
Score: 0.007